Navigation Links
State Support for Programs to Decrease Tobacco Use Among Teens and Adults on the Decline According to Trend Report Released Today
Date:8/12/2008

prioritize their commitment to protect their citizens from tobacco related death and illness. The emotional and economic impact this has on our country is staggering," added Toomey. "It is now in the states' hands to improve the health of our nation by going smokefree by 2010. We are here to support our legislative partners every step of the way."

It should be noted that a handful of states have made important strides so far this year. The American Lung Association applauds Iowa and Nebraska for approving comprehensive smokefree laws prohibiting smoking in almost all public places and workplaces, including restaurants and bars. With the addition of these two states, 23 states, the District of Columbia and Puerto Rico have now met the American Lung Association's Smokefree Air 2010 Challenge.

Also in 2008, New York and Massachusetts as well as the District of Columbia increased their cigarette taxes by $1.00 per pack or more. New York now replaces New Jersey as the state with the highest cigarette tax at $2.75 per pack. Large increases in state cigarette taxes are directly linked to decreased smoking especially among children.

A PDF copy of 2008 SLATI Mid-Term Report is available online at: http://slati.lungusa.org/midtermreports.asp. This website is also the home of the online version of SLATI, which is updated on a regular basis to reflect changes in state tobacco control laws throughout the year. SLATI is the only up-to-date and comprehensive summary of state tobacco control laws. Production of the 2008 SLATI Mid-Term Report is supported by a grant from the Robert Wood Johnson Foundation in Princeton, New Jersey.

For more information on the American Lung Association's Smokefree Air 2010 Challenge, go to http://www.lungusa.org/smokefree2010.

About the American Lung Association: Beginning our secon
'/>"/>

SOURCE American Lung Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Six States Named to National Asthma & Allergy Honor Roll
2. State of Ohio Recognizes Cincinnati Sub-Zero for Excellence in International Sales
3. 1 in 5 young men has had recent prostate cancer test
4. Statement by the Service Employees International Union (SEIU) Concerning Allegations About SEIU Local 6434, United Long Term Care Workers Union
5. Obese Men Face Twin Threat From Prostate Cancer
6. Statement of concern on detention of Drs. Kamiar and Arash Alaei by Iranian authorities
7. U.S. Preventive Medicine Supports Testing Older Men for Prostate Cancer
8. Study Links Agent Orange to Prostate Cancer in Vietnam Vets
9. US Preventive Services Task Force updates prostate cancer screening recommendations
10. New Guidelines Rule Out Prostate Screening for Men Over 75
11. Latest CDC Report on HIV Incidence Grossly Excludes Hispanics in 2006, the Fastest Growing Ethnic Population in the United States and its Territories
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 2A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 3A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 4A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8